Safe Surf Rated Back To Home Page Family Friendly Site

Positively Positive
- Living with HIV
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News Bradford McIntyre

Nagasaki University Awarded Clinical Research Grant to Study Cell-Enhanced Reconstruction in HIV Therapy-Induced Facial Atrophy Using Celution® 800 System

SAN DIEGO & NAGASAKI, Japan, Apr 09, 2008 (BUSINESS WIRE) - Nagasaki University will sponsor and perform a clinical study on the use of cell-enhanced reconstruction in HIV therapy-induced facial atrophy, a condition where adipose (fat) tissue becomes unevenly lost, leaving patients with a gaunt appearance. The study will be funded through a three year, 58.5 million yen grant (approx. U.S. $600,000), which was awarded to Nagasaki University by the Japanese Ministry of Health, Labour and Welfare. Cytori's research team will collaborate with Nagasaki University to optimize the treatment formulation prior to commencement of clinical research.

The need for this research is based upon increasing demand by patients with HIV seeking new options to restore their facial appearance after long-term use of potent protease inhibitor drugs. This represents an important unmet medical need, for which cell-enhanced reconstruction may provide a potential solution. Cell-enhanced reconstruction combines a patient's own stem and regenerative cells with their own fat tissue as a matrix. It has been used on many patients for the restoration and reconstruction of soft tissue loss. The stem and regenerative cell will be made available in real-time from the patient's own adipose tissue using the Celution® 800 System from Cytori Therapeutics (NASDAQ: CYTX).

"The treatment of facial wasting in patients with HIV who have undergone protease inhibitor therapy represents another potential medical application within the field of reconstructive surgery for adipose-derived stem and regenerative cells and our Celution® 800 System," said Marc H. Hedrick, M.D., president, Cytori. "The goal of this study will be to show cell-enhanced reconstruction in HIV-induced facial wasting is clinically feasible and effective."

Adipose tissue is a rich source of regenerative cells that have been shown pre-clinically to improve volume retention and graft persistence as part of a cell-enhanced reconstruction. These adipose-derived regenerative cells include adult stem cells in addition to other important cell types. To facilitate a cell-enhanced reconstruction, Cytori developed its European-approved Celution® 800/CRS System to automate and standardize the process by which physicians can access their patient's adipose-derived stem and regenerative cells at the bedside.


Cytori's (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution ® 800 System is being introduced in Europe into the reconstructive surgery market while the Celution ® 900 System will be launched in Japan for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

SOURCE: Cytori

Tom Baker, 858-875-5258

Copyright Business Wire 2008

...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik

Copyright © 2003-2019 Bradford McIntyre. All rights reserved.